Baudax Bio Inc. (NASDAQ:BXRX) finished Wednesday with an addition of $0.03 to close at $0.58, an upside of 5.66 percent. An average of 808,840 shares of common stock have been traded in the last five days. There was a gain of $0.0517 in the past week. The last 20 days have seen an average of 829,160 shares traded, while the 50-day average volume stands at 3,754,930.
BXRX stock has decreased by -5.76% in the last month. The company shares reached their 1-month lowest point of $0.5200 on 10/06/21. With the stock rallying to its 52-week high on 02/09/21, shares of the company touched a low of $0.50 and a high of $2.85 in 52 weeks. In spite of this, the price is down -79.51% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Baudax Bio Inc. (BXRX) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 93.44.
The quick ratio of Baudax Bio Inc. for the three months ended June 29 was 2.90, and the current ratio was 3.10, indicating that the company is able to meet its debt obligations. Baudax Bio Inc.’s EBITDA margin for the year ending June 29 is -10801.83%. Its gross profit as reported stood at -$1.24 million compared to revenue of $0.49 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Baudax Bio Inc.’s return on assets was -53.90%.
For the three-month period that ended June 29, Baudax Bio Inc. had $12.15 million in cash. The analyst consensus anticipated Baudax Bio Inc.’s latest quarter earnings to come in at -$0.2 per share, but it turned out to be -$0.23, a -15.00% surprise. For the quarter, EBITDA amounted to -$15.61 million. Shareholders own equity worth $84.4 million.
From a technical analysis perspective, let’s take a brief look at Baudax Bio Inc. (BXRX) price momentum. RSI 9-day as of the close on 13 October was 56.10%, suggesting the stock is Neutral, with historical volatility in this time frame at 44.54%.
As of today, BXRX’s price is $0.5559 +9.71% or $0.0517 from its 5-day moving average. BXRX is currently trading -5.06% lower than its 20-day SMA and -31.37% lower than its 100-day SMA. However, the stock’s current price level is -4.56% below the SMA50 and -43.30% below the SMA200.
The stochastic %K and %D were 38.88% and 31.85%, respectively, and the average true range (ATR) was 0.0318. With the 14-day stochastic at 58.18% and the average true range at 0.0344, the RSI (14) stands at 50.38%. The stock has reached 0.0110 on the 9-day MACD Oscillator while the 14-day reading was at -0.0016.
JMP Securities launched coverage on Baudax Bio Inc. (NASDAQ: BXRX) in its analyst report released on May 15, 2020. The firm assigned the stock a a Mkt outperform rating.The consensus rating for Baudax Bio Inc. (BXRX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BXRX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is BXRX’s price target for the next 12 months?
Analysts predict a range of price targets between $2.00 and $2.00, with a median target of $2.00. Taking a look at these predictions, the average price target given by analysts for Baudax Bio Inc. (BXRX) stock is $2.00.